Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. (Q46848022)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. |
scientific article |
Statements
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial (English)
Giuseppe Viale
Aron Goldhirsch
Meredith M Regan
Karen N Price
Monica Castiglione-Gertsch
Patrizia Dell'Orto
Stephen Braye
Barbara Del Curto
Beat Thürlimann
Birgitte B Rasmussen
Anne E Lykkesfeldt
Katrine L Henriksen
Magali Lacroix-Triki
Hans J Altermatt
Richard D Gelber
Barry A Gusterson
Alan S Coates
BIG 1-98 Collaborative and International Breast Cancer Study Groups
20 December 2007